Kinstellar, working with Addleshaw Goddard, has advised Phoenix Equity Partners Limited on its acquisition of FutureMeds, including subsidiaries in Bulgaria and Ukraine. DLA Piper reportedly advised the sellers.
According to Kinstellar, the transaction represents a strategic expansion of Phoenix’s investment footprint in the healthcare and life sciences sector, supporting FutureMeds’ ambition to broaden access to clinical trials across Europe. FutureMeds is Europe’s first dedicated independent site management organization, offering access to advanced clinical research infrastructure across multiple jurisdictions.
The Kinstellar team included Bulgaria-based Managing Partner Diana Dimova, Counsel Atanas Mihaylov, Senior Associates Denitsa Kuzeva, Simeon Vachev, and Debora Dineva, Consultant Vanya Evtimova, and Junior Associate Simona Damyanova and Ukraine-based Managing Partner Olena Kuchynska, Partner Natalia Kirichenko, Counsel Yulia Eismont, Managing Associate Lyudmyla Dzhurylyuk, Senior Associates Olena Stanishevska and Tetiana Kolha, and Associates Olena Tsygulska, Diana Malysh, and Danylo Kholodyan.
The Addleshaw Goddard team included Poland-based Managing Associate Magda Szewczyk and Senior Associate Lukasz Czerepak as well as lawyers in the UK, Spain, and Germany.
Kinstellar could not provide additional information on the matter.
